IMPACT OF TYPE 2 DIABETES MELLITUS ON RIFAMPICIN PHARMACOKINETICS AND BIOCHEMICAL PATHWAYS IN PULMONARY TUBERCULOSIS PATIENTS

Authors

  • Dr. Azad Kumar Singh
  • Dr. Satish Kumar Yadav
  • Ms. Sonam Verma
  • Dr. Princ Bgheal

DOI:

https://doi.org/10.53555/gcv48408

Abstract

The co-occurrence of pulmonary tuberculosis (PTB) and type 2 diabetes mellitus (T2DM) presents a significant public health challenge. T2DM may alter the pharmacokinetics (PK) of antitubercular drugs, particularly rifampicin, compromising therapeutic efficacy.

Objective: To investigate the impact of T2DM on rifampicin PK and biochemical pathways in PTB patients.
Methods: A prospective observational study was conducted involving 60 PTB patients (30 with T2DM and 30 non-diabetic controls). Plasma rifampicin concentrations were analyzed using LC-MS/MS at multiple time points post-dosing. Biochemical markers including CRP, IL-6, fasting glucose, and liver function tests were assessed. Non-compartmental PK analysis was performed.
Results: Diabetic patients showed significantly delayed rifampicin Tmax (mean 3.1 h vs 2.2 h, p < 0.01) and reduced Cmax (6.8 ± 2.1 μg/mL vs 9.5 ± 2.6 μg/mL, p < 0.001). AUC₀–₂₄ was also lower in the T2DM group (48.2 ± 11.3 μg·h/mL vs 61.4 ± 10.7 μg·h/mL, p < 0.05). Higher levels of systemic inflammation (CRP, IL-6) correlated inversely with rifampicin exposure.

Conclusion: T2DM significantly impairs rifampicin pharmacokinetics in PTB patients, likely through altered absorption and inflammatory modulation. Dose optimization and therapeutic drug monitoring (TDM) should be considered in this population.

Author Biographies

  • Dr. Azad Kumar Singh

    (Assistant Professor) Department of Biochemistry, Government Medical College, Badaun

    (Uttar Pradesh)

  • Dr. Satish Kumar Yadav

    (Assistant Professor) Department of Biochemistry, Government Medical College & Super Facility Hospital Chakrapanpur, Azamgarh.

  • Ms. Sonam Verma

     (Tutor) Department of Biochemistry, Sukh Sagar Medical College and hospital Jabalpur, Madhya Pradesh.

  • Dr. Princ Bgheal

    (Ph.D. scholar) Department of Pharmacology, Rama Medical college, Kanpur. 

References

1. World Health Organization. Global TB report 2022. Geneva: WHO; 2022.

2. Mandal S, Rao R, Joshi R. Re-estimating tuberculosis incidence and mortality in India during 2011-2022: a modelling study. Indian J Community Med 2023; 48:436–42.

3. World Health Organization. WHO consolidated guidelines on tuberculosis: Module 1: Prevention. Tuberculosis preventive treatment. Geneva: WHO; 2020.

4. Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India. National strategic plan for tuberculosis elimination 2017-2025.

5. Chadha VK, Kumar P, Jagannatha PS, Vaidyanathan PS, Unnikrishnan KP. Average annual risk of tuberculous infection in India. Int J Tube Lung Dis 2005; 9:116–8

6. Ashith k.; Alan Rosani2; Preeti Patel; Roopma Wadhwa; Rifampicin: November 12, 2023.

7. Zheng, J., Wang, M., & Lu, Y. (2020). Systemic inflammation and altered drug metabolism: A meta-analysis of IL-6, CRP and hepatic enzyme expression. Clinical Pharmacokinetics, 59(12), 1523–1534.

Downloads

Published

2025-08-26

How to Cite

Dr. Azad Kumar Singh, Dr. Satish Kumar Yadav, Ms. Sonam Verma, & Dr. Princ Bgheal. (2025). IMPACT OF TYPE 2 DIABETES MELLITUS ON RIFAMPICIN PHARMACOKINETICS AND BIOCHEMICAL PATHWAYS IN PULMONARY TUBERCULOSIS PATIENTS. Journal of Population Therapeutics and Clinical Pharmacology, 32(7), 1149-1153. https://doi.org/10.53555/gcv48408
More Citation Formats

Issue

Section

Articles

How to Cite

Dr. Azad Kumar Singh, Dr. Satish Kumar Yadav, Ms. Sonam Verma, & Dr. Princ Bgheal. (2025). IMPACT OF TYPE 2 DIABETES MELLITUS ON RIFAMPICIN PHARMACOKINETICS AND BIOCHEMICAL PATHWAYS IN PULMONARY TUBERCULOSIS PATIENTS. Journal of Population Therapeutics and Clinical Pharmacology, 32(7), 1149-1153. https://doi.org/10.53555/gcv48408